Galectin investor Richard Uihlein holds 49.3% stake

Richard E. Uihlein reports beneficial ownership of 54,673,646.00 shares of Galectin Therapeutics Inc. common stock, representing approximately 49.30% of the outstanding class.

Accepted by SEC EDGAR 08/04/2026 - 08:30 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Richard E. Uihlein reports beneficial ownership of 54,673,646.00 shares of Galectin Therapeutics Inc. common stock, representing approximately 49.30% of the outstanding class. He has sole voting and sole dispositive power over these shares, which are held for investment purposes rather than to change or influence control.

The stake consists of 44,736,553 shares of common stock and 9,937,093 shares issuable upon conversion of warrants, options and other convertible securities. On July 31, 2026, he converted debt of approximately $105.8, consisting of $91.0 million of principal and approximately $14.8 million of accrued interest, into 34,376,167 shares of common stock. His investment is described as funded with personal funds.

Key Figures

Beneficial ownership: 54,673,646.00 shares Ownership percentage: 49.30 % Outstanding common shares held: 44,736,553 shares +5 more

8 metrics

Beneficial ownership 54,673,646.00 shares Total Galectin common stock beneficially owned by Richard E. Uihlein

Ownership percentage 49.30 % Percent of Galectin common stock class represented by Uihlein’s holdings

Outstanding common shares held 44,736,553 shares Portion of Uihlein’s stake in currently issued common stock

Shares issuable from convertibles 9,937,093 shares Shares issuable upon conversion of warrants, options and other convertible securities

Debt converted – principal $91.0 million Principal amount of debt converted into Galectin common stock on July 31, 2026

Debt converted – interest approximately $14.8 million Accrued interest included in the debt converted into Galectin common stock

Shares issued on conversion 34,376,167 shares Galectin common shares received upon debt conversion on July 31, 2026

Event date 07/31/2026 Date of the event that triggered the amended beneficial ownership report

Key Terms

Beneficial ownership, Sole Voting Power, Sole Dispositive Power, convertible securities, +1 more

5 terms

Beneficial ownership financial

"aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole Voting Power financial

"Number of Shares Beneficially Owned with Sole Voting Power 54,673,646.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Number of Shares Beneficially Owned with Sole Dispositive Power 54,673,646.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

convertible securities financial

"shares issuable upon conversion of warrants, options, and other convertible securities"

Convertible securities are bonds or preferred shares that can be exchanged for a company’s common stock at a predetermined price or under specified conditions. They matter because they combine the steadiness of a loan or fixed dividend with the potential upside of ownership; like a safety‑net that carries a one‑time ticket to become a shareholder, they affect expected returns and can dilute existing stock if converted.

Schedule 13G regulatory

"previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Galectin Therapeutics (GALT) does Richard E. Uihlein own?

Richard E. Uihlein beneficially owns about 49.30% of Galectin Therapeutics’ common stock. This equals 54,673,646.00 shares, including both currently outstanding common shares and additional shares that could be issued from warrants, options and other convertible securities he holds overall.

How many Galectin Therapeutics (GALT) shares does Richard E. Uihlein hold and how is his stake structured?

He beneficially owns 54,673,646.00 Galectin shares, made up of 44,736,553 common shares plus 9,937,093 shares issuable upon conversion of warrants, options and other convertible securities, giving him a large mix of current and potential future equity.

What transaction did Richard E. Uihlein complete on July 31, 2026 involving GALT?

On July 31, 2026, Richard E. Uihlein converted debt of approximately $105.8, consisting of $91.0 million principal and about $14.8 million accrued interest, into 34,376,167 Galectin common shares, increasing the number of shares held as part of his investment.

What is the source of funds for Richard E. Uihlein’s Galectin Therapeutics (GALT) investment?

The disclosed source of funds for Richard E. Uihlein’s Galectin investment is Personal Funds. This indicates that his ownership position, including the securities referenced, is associated with capital he provided personally rather than institutional or third-party financing.

Is Richard E. Uihlein seeking to change control of Galectin Therapeutics (GALT) with this stake?

The disclosure states the shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of Galectin Therapeutics, clarifying his stated intention regarding corporate control despite his large ownership.

What voting and dispositive powers does Richard E. Uihlein have over his GALT shares?

Richard E. Uihlein is reported to have sole voting power and sole dispositive power over 54,673,646.00 Galectin shares. This means he alone decides how these shares are voted and whether, when, and how they may be sold or otherwise disposed of.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

GALECTIN THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

363225202

(CUSIP Number)

Richard E. Uihlein
12575 Uline Drive,
Pleasant Prairie, WI, 53158
262-612-4200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/31/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 363225202

1

Name of reporting person

Richard E. Uihlein

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 54,673,646.00
8	Shared Voting Power
9	Sole Dispositive Power 54,673,646.00
10	Shared Dispositive Power

11

Aggregate amount beneficially owned by each reporting person

54,673,646.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

49.30 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: COMMON STOCK
(b)	Name of Issuer: GALECTIN THERAPEUTICS INC
(c)	Address of Issuer's Principal Executive Offices: 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GEORGIA , 30071.
Item 2.	Identity and Background
(a)	Richard E. Uihlein
(b)	12575 Uline Drive, Pleasant Prairie, WI 53158
(c)	None
(d)	None
(e)	None
(f)	United States
Item 3.	Source and Amount of Funds or Other Consideration
	Personal Funds
Item 4.	Purpose of Transaction
	The Shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of the Company.
Item 5.	Interest in Securities of the Issuer
(a)	54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%.
(b)	54,673,646 shares of common stock, which includes 44,736,553 shares of common stock and 9,937,093 shares of common stock issuable upon conversion of warrants, options, and other convertible securities). The Reporting Person's aggregate beneficial ownership as calculated in accordance with Section 13(d) is approximately 49.3%.
(c)	On July 31, 2026, the Reporting person converted debt in the amount of approximately $105.8 (consitsing of $91.0 million of principal and approximately $14.8 million of accrued interest) into 34,376,167 shares of common stock.
(d)	None
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	None
Item 7.	Material to be Filed as Exhibits.
	None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard E. Uihlein

Signature:	/s/ Richard E. Uihlein
Name/Title:	Richard E. Uihlein
Date:	08/04/2026